Laura Machin Galarza | Pharmacology | Young Scientist Award

Published on by World Top Scientists

Assist. Prof. Dr. Laura Machin Galarza | Pharmacology | Young Scientist Award

Laura Machin Galarza | University of Havana | Cuba

Dr. Laura Machin Galarza is an Assistant Professor and Researcher at the Institute of Pharmacy and Foods, University of Havana, specializing in pharmaceutical sciences and parasitology. She holds a Bachelor’s, Master’s, and Doctorate in Pharmaceutical Sciences from the University of Havana, where her academic journey has been marked by excellence and commitment to translational research. Dr. Machin has undertaken prestigious research stays at institutions in Austria, Germany, China, and Cuba, contributing to international collaborations focused on pharmacology, toxicology, and biopharmaceutical innovation. Her professional experience includes leadership in multidisciplinary projects exploring the antiprotozoal and antileishmanial potential of natural and synthetic compounds, advanced drug delivery systems, and pharmacological recycling strategies. She has authored multiple peer-reviewed publications in high-impact journals such as Pharmaceuticals, Molecules, and Experimental Parasitology, demonstrating expertise in medicinal chemistry and drug development. Dr. Machin’s work has been recognized through contributions to award-winning research honored by the Cuban Academy of Sciences. She actively serves in academic editorial processes, participates in professional scientific societies, and holds certifications that reflect her dedication to research excellence, innovation, and scientific leadership in the field of pharmaceutical sciences.

Profiles: Google Scholar | Scopus 

Featured Publications

1. B. Salehi, L. Machin, L. Monzote, J. Sharifi-Rad, S. M. Ezzat, M. A. Salem, et al., “Therapeutic potential of quercetin: new insights and perspectives for human health,” ACS Omega, vol. 5, no. 20, pp. 11849–11872, 2020.

2. B. Tamargo, L. Monzote, A. Piñón, L. Machín, M. García, R. Scull, W. N. Setzer, “In vitro and in vivo evaluation of essential oil from Artemisia absinthium L. formulated in nanocochleates against cutaneous leishmaniasis,” Medicines, vol. 4, no. 2, p. 38, 2017.

3. L. Machín, R. Nápoles, L. Gille, L. Monzote, “Leishmania amazonensis response to artemisinin and derivatives,” Parasitology International, vol. 80, p. 102218, 2021.

4. G. Geroldinger, M. Tonner, J. Quirgst, M. Walter, S. De Sarkar, L. Machín, et al., “Activation of artemisinin and heme degradation in Leishmania tarentolae promastigotes: a possible link,” Biochemical Pharmacology, vol. 173, p. 113737, 2020.

5. L. Machín, B. Tamargo, A. Piñón, R. C. Atíes, R. Scull, W. N. Setzer, L. Monzote, “Bixa orellana L. (Bixaceae) and Dysphania ambrosioides (L.) Mosyakin & Clemants (Amaranthaceae) essential oils formulated in nanocochleates against Leishmania amazonensis,” Molecules, vol. 24, no. 23, p. 4222, 2019.

Ksenia Blinova | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Ksenia Blinova | Pharmacology | Best Researcher Award

Associate Director at US Food and Drug Administration, United States

Dr. Ksenia Blinova, Ph.D., is the Associate Director for the Division of Applied Regulatory Science at the U.S. Food and Drug Administration, where she leads innovative research, regulatory reviews, and scientific consultations that advance translational science in support of public health. With a strong academic foundation in physics, mathematics, and cardiac electrophysiology, she has built a distinguished career focused on bridging fundamental science with regulatory applications. Since joining the FDA as a Commissioner’s Fellow, Dr. Blinova has held key leadership roles, including Deputy Director of the Division of Biomedical Physics, where she led multidisciplinary teams in developing over forty regulatory science tools that improved the evaluation of medical devices across fields such as cardiology, neurostimulation, diagnostics, and patient monitoring. Her career reflects a unique combination of scientific excellence, leadership, and commitment to advancing safe and effective medical products, making her an influential figure in the field of regulatory science.

Professional Profile 

Scopus Profile | ORCID Profile 

Education

Dr. Ksenia Blinova earned her undergraduate and doctoral degrees in Physics and Mathematics from Moscow State University, where she developed a strong foundation in quantitative sciences and analytical problem-solving. She further advanced her academic journey through a postdoctoral fellowship at the National Heart, Lung, and Blood Institute at the National Institutes of Health. Her research during this period centered on cardiac electrophysiology and metabolism, areas that deepened her expertise in biomedical applications of physical sciences. This educational trajectory not only equipped her with advanced technical knowledge but also gave her a unique interdisciplinary perspective that integrates rigorous physics and mathematical methodologies with life sciences and clinical research. Her educational background has been pivotal in shaping her ability to address complex regulatory and scientific challenges, contributing to her capacity for innovation and leadership in translational science and regulatory policy at the intersection of medicine, technology, and public health.

Experience

Dr. Blinova has built a distinguished career at the U.S. Food and Drug Administration, beginning as a Commissioner’s Fellow and progressing to influential leadership roles. As Deputy Director of the Division of Biomedical Physics in the Center for Devices and Radiological Health, she guided a multidisciplinary team in creating innovative regulatory science tools that addressed critical challenges in medical device safety and effectiveness. Her leadership was instrumental in developing methods and resources for fields such as cardiology, neurostimulation, ophthalmology, in-vivo diagnostics, and advanced patient monitoring. Currently serving as Associate Director for the Division of Applied Regulatory Science in the Office of Clinical Pharmacology, she oversees research, scientific consultations, and regulatory reviews that support the FDA’s translational science priorities. Through these roles, she has combined her technical expertise with strategic vision, ensuring that scientific advancements translate into practical regulatory applications that safeguard patient health and promote medical innovation.

Research Focus

Dr. Blinova’s research focuses on advancing translational and regulatory science to accelerate the safe and effective delivery of medical products to patients. Her early work in cardiac electrophysiology and metabolism provided insights into fundamental mechanisms of heart function, laying the groundwork for her later contributions in biomedical physics and device evaluation. At the FDA, she has led research efforts that integrate computational modeling, experimental studies, and regulatory tool development to address complex safety and efficacy challenges in medical devices and drug-device combinations. Her team has developed innovative approaches to evaluate technologies in cardiology, neurostimulation, electrical safety, diagnostics, and patient monitoring, ensuring that regulatory science keeps pace with rapid technological advances. By bridging basic science, applied research, and policy, her work exemplifies the role of regulatory science in translating innovation into tangible benefits for patients and healthcare systems, while maintaining a focus on safety, effectiveness, and public health impact.

Award and Honor

Throughout her career, Dr. Blinova has been recognized for her leadership, innovation, and contributions to regulatory science. Her accomplishments include guiding the development of over forty regulatory tools that have had a lasting impact on how medical devices are assessed for safety and effectiveness. These achievements reflect not only her scientific expertise but also her ability to collaborate across disciplines to solve pressing healthcare challenges. Her recognition within the FDA and broader scientific community underscores her role as a leader who consistently advances the field of translational science. Honors and awards in her career highlight her success in bridging science and regulation, her dedication to patient safety, and her influence in shaping modern approaches to medical product evaluation. These distinctions serve as a testament to her sustained contributions, her commitment to innovation, and her growing impact as a respected figure in regulatory and biomedical research.

Publication Top Notes

  • Title: Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential
    Authors: M. Iveth Garcia, Bhavya Bhardwaj, Keri Dame, Verena Charwat, Brian A. Siemons, Ishan Goswami, Omnia A. Ismaiel, Sabyasachy Mistry, Tromondae K. Feaster, Kevin E. Healy, et al.
    Year: 2025

  • Title: In Vitro Assay Development to Study Pulse Field Ablation Outcome Using Solanum Tuberosum
    Authors: Akshay Narkar, Abouzar Kaboudian, Yasaman Ardeshirpour, Maura Casciola, Tromondae Feaster, Ksenia Blinova
    Year: 2024
    Citations: 2

  • Title: Nonclinical evaluation of chronic cardiac contractility modulation on 3D human engineered cardiac tissues
    Authors: Tromondae K. Feaster, Jourdan K. Ewoldt, Anna Avila, Maura Casciola, Akshay Narkar, Christopher S. Chen, Ksenia Blinova
    Year: 2024

  • Title: Comprehensive Collection of Current Methods for Contractility and Electrophysiology Recordings in Human Cardiac Cells
    Authors: Ksenia Blinova, J. Pierson, A. Narkar
    Year: 2023

  • Title: Human in vitro assay for irreversible electroporation cardiac ablation
    Authors: Maura Casciola, Tromondae K. Feaster, M. J. Caiola, D. Keck, Ksenia Blinova
    Year: 2023

  • Title: Acute effects of cardiac contractility modulation stimulation in conventional 2D and 3D human induced pluripotent stem cell-derived cardiomyocyte models
    Authors: Tromondae K. Feaster, N. Feric, I. Pallotta, A. Narkar, M. Casciola, M. P. Graziano, R. Aschar-Sobbi, Ksenia Blinova
    Year: 2022

  • Title: Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2022

  • Title: Human in vitro neurocardiac coculture (iv NCC) assay development for evaluating cardiac contractility modulation
    Authors: Akshay Narkar, Tromondae K. Feaster, Maura Casciola, Ksenia Blinova
    Year: 2022

  • Title: Human cardiomyocytes are more susceptible to irreversible electroporation by pulsed electric field than human esophageal cells
    Authors: Maura Casciola, Devin Keck, Tromondae K. Feaster, Ksenia Blinova
    Year: 2022

  • Title: Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)
    Authors: Akshay Narkar, James M. Willard, Ksenia Blinova
    Year: 2022

  • Title: Cardiovascular medical devices: Regulatory science research overview in the office of science and engineering laboratories (OSEL) at the food and drug administration (FDA)
    Authors: K. Aycock, Ksenia Blinova, M. Casciola, B. Craven, M. Di Prima, G. D’Souza, N. Duraiswamy, M. Farahmand, P. Hariharan, L. Herbertson, et al.
    Year: 2021

  • Title: Acute effects of cardiac contractility modulation on human induced pluripotent stem cell–derived cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2021

Conclusion

Dr. Ksenia Blinova has demonstrated exceptional expertise and leadership in translational and regulatory science, particularly in the evaluation and development of cardiac therapies and medical devices. Her extensive body of research, including numerous high-impact publications on human in vitro cardiac models, contractility modulation, and electroporation assays, reflects a consistent focus on innovative approaches that bridge fundamental science with practical clinical and regulatory applications. She has led multidisciplinary teams to develop tools and methodologies that enhance patient safety, accelerate medical innovation, and provide reliable scientific evidence for regulatory decisions. Her work not only advances the understanding of cardiac electrophysiology and device performance but also sets new standards for predictive, nonclinical cardiac research. Overall, Dr. Blinova’s contributions exemplify the qualities of a pioneering researcher whose scientific rigor, leadership, and commitment to public health make her highly deserving of recognition in any Best Researcher Award.

Dr. Anca-Roxana Petrovici | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Anca-Roxana Petrovici | Pharmacology | Best Researcher Award

Dr. Anca-Roxana Petrovici, “Petru Poni” Institute of Macromolecular Chemistry, Romania

Dr. Anca-Roxana Petrovici is a prominent researcher at the “Petru Poni” Institute of Macromolecular Chemistry in Romania. With a strong focus on macromolecular science, she has made significant contributions to the field through her innovative research and publications, aiming to advance knowledge and applications in polymer chemistry.

Profile

Scopus

Orcid

Education 🎓

Dr. Petrovici obtained her Ph.D. in Macromolecular Chemistry, where her thesis focused on the synthesis and characterization of novel polymer materials. Her academic journey has been marked by a commitment to excellence and a passion for advancing the field of polymer science.

Experience 💼

With extensive experience at the “Petru Poni” Institute, Dr. Petrovici has engaged in various research projects and collaborations, contributing to the development of new materials and applications. Her role has also involved mentoring students and collaborating with industry partners to apply scientific findings practically.

Research Interest 🔬

Dr. Petrovici’s research interests lie primarily in the synthesis, characterization, and application of macromolecular materials. She focuses on the development of innovative polymers with specific functionalities, exploring their potential in diverse fields such as biomedicine, packaging, and nanotechnology.

Awards 🏆

Throughout her career, Dr. Petrovici has received numerous accolades recognizing her contributions to polymer chemistry. While specific awards are not listed here, her work has been widely cited, reflecting her influence in the scientific community.

Publication Top notes 📚

Correction: Simionescu et al. The Multifaceted Role of Extracellular Vesicles in Glioblastoma: microRNA Nanocarriers for Disease Progression and Gene Therapy. Pharmaceutics 2021, 13, 988

Phenolic Composition and Bioactivities of Invasive Ailanthus altissima (Mill.) Swingle Leaf Extracts Obtained by Two-Step Sequential Extraction

In Vitro Screening of Ecotoxic and Cytotoxic Activities of Ailanthus altissima Leaf Extract against Target and Non-Target Plant and Animal Cells

Enhancing the Antioxidant Potential of Weissella confusa PP29 Probiotic Media through Incorporation of Hibiscus sabdariffa L. Anthocyanin Extract

Complexes of Ibuprofen Thiazolidin-4-One Derivatives with β-Cyclodextrin: Characterization and In Vivo Release Profile and Biological Evaluation

NEW METAL COMPLEXES WITH ARIL-ACETIC STRUCTURE: PREPARATION, CHARACTERIZATION, AND IN VITRO ANTIINFLAMMATORY EFFECTS

Dextran-Chitosan Composites: Antioxidant and Anti-Inflammatory Properties

3D Matrices for Enhanced Encapsulation and Controlled Release of Anti-Inflammatory Bioactive Compounds in Wound Healing

Dextran Formulations as Effective Delivery Systems of Therapeutic Agents

Probiotic Properties of Weissella confusa PP29 on Hibiscus sabdariffa L. Media